Michael Byrnes
CIK 1619893 · Chief Financial Officer · last filed 2026-01-09
Michael Byrnes is a Chief Financial Officer who has filed 27 SEC Form 4 insider transactions across 2 companies since 2021. The most recent filing, for PBAXW, was dated Jan 9, 2026. Across all open-market trades the lifetime net is +$33.3K, making them a net buyer over the disclosed history.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$0
2
27
$33.3K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CERO THERAPEUTICS HOLDINGS, INC. (PBAXW) Delisted | Director | — | $0.05 | — | $0 | 6 | 2026-01-09 |
| eFFECTOR Therapeutics, Inc. (EFTRW) Delisted | Chief Financial Officer | 3,117 | $0.00 | $2 | $33.3K | 11 | 2024-05-17 |
Recent Filings
27 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-01-09 | CERO THERAPEUTICS HOLDINGS, INC. (PBAXW) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-06-02 | CERO THERAPEUTICS HOLDINGS, INC. (PBAXW) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-03-06 | CERO THERAPEUTICS HOLDINGS, INC. (PBAXW) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-02-26 | CERO THERAPEUTICS HOLDINGS, INC. (PBAXW) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-12-04 | CERO THERAPEUTICS HOLDINGS, INC. (PBAXW) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-05-17 | eFFECTOR Therapeutics, Inc. (EFTRW) Delisted | Grant (A) | +1,387 | $2.3K | EDGAR |
| 2024-03-27 | CERO THERAPEUTICS HOLDINGS, INC. (PBAXW) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-02-21 | eFFECTOR Therapeutics, Inc. (EFTRW) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-11-16 | eFFECTOR Therapeutics, Inc. (EFTRW) Delisted | Grant (A) | +4,524 | $2.2K | EDGAR |
| 2023-05-16 | eFFECTOR Therapeutics, Inc. (EFTRW) Delisted | Grant (A) | +4,863 | $2.2K | EDGAR |